Clinical trial
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly…
NCT03739814 · National Cancer Institute (NCI), NIH · Suspended
Key facts
| NCT number | NCT03739814 |
|---|---|
| Title | Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia |
| Official title | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia |
| Intervention type | Biological |
| Interventions | Blinatumomab, Inotuzumab Ozogamicin |
| Enrollment | 64 |
| Start date | May 8, 2019 |
| Primary completion | Feb 1, 2027 |
| Completion | Feb 1, 2027 |
| First posted | Nov 14, 2018 |
| Last update posted | Feb 3, 2026 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: